PropThink: FDA Warning Letter Weakens Shares of Akorn

[ACN Newswire] – By Jake KingThis week, the FDA posted a warning letter to Akorn, Inc (NASDAQ:AKRX) dated October 2, warning the company that it is manufacturing an unapproved drug, Pilocarpine Hydrochloride Ophthalmic … more

View todays social media effects on AKRX

View the latest stocks trending across Twitter. Click to view dashboard